AxoGen, Inc. (NASDAQ:AXGN) CEO Karen L. Zaderej Sells 3,500 Shares

AxoGen, Inc. (NASDAQ:AXGN) CEO Karen L. Zaderej sold 3,500 shares of AxoGen stock in a transaction that occurred on Tuesday, December 29th. The stock was sold at an average price of $17.81, for a total transaction of $62,335.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Shares of NASDAQ AXGN opened at $17.90 on Friday. AxoGen, Inc. has a 52-week low of $7.16 and a 52-week high of $18.43. The company has a debt-to-equity ratio of 0.42, a quick ratio of 6.81 and a current ratio of 7.45. The company’s 50 day moving average price is $16.00 and its 200-day moving average price is $12.85.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Tuesday, November 3rd. The medical equipment provider reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.18. The company had revenue of $33.43 million during the quarter, compared to analyst estimates of $30.10 million. AxoGen had a negative net margin of 22.98% and a negative return on equity of 19.83%. On average, analysts predict that AxoGen, Inc. will post -0.61 earnings per share for the current fiscal year.

Several research firms recently commented on AXGN. Guggenheim initiated coverage on shares of AxoGen in a research report on Thursday, October 22nd. They set a “buy” rating and a $24.00 target price on the stock. BidaskClub downgraded shares of AxoGen from a “buy” rating to a “hold” rating in a research report on Wednesday, December 16th. Finally, Canaccord Genuity restated a “hold” rating and issued a $13.00 price target on shares of AxoGen in a research report on Wednesday, September 16th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $17.13.

Several large investors have recently added to or reduced their stakes in the company. Paloma Partners Management Co bought a new stake in shares of AxoGen in the 3rd quarter valued at $187,000. California State Teachers Retirement System increased its stake in shares of AxoGen by 5.3% in the 3rd quarter. California State Teachers Retirement System now owns 54,879 shares of the medical equipment provider’s stock valued at $638,000 after acquiring an additional 2,768 shares in the last quarter. Squarepoint Ops LLC increased its stake in shares of AxoGen by 67.7% in the 3rd quarter. Squarepoint Ops LLC now owns 17,955 shares of the medical equipment provider’s stock valued at $209,000 after acquiring an additional 7,251 shares in the last quarter. Morgan Stanley increased its stake in shares of AxoGen by 14.4% in the 3rd quarter. Morgan Stanley now owns 209,911 shares of the medical equipment provider’s stock valued at $2,441,000 after acquiring an additional 26,396 shares in the last quarter. Finally, First Light Asset Management LLC bought a new stake in shares of AxoGen in the 3rd quarter valued at $20,113,000. Institutional investors own 77.74% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, provides surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Featured Story: Why is the conference call important?

Insider Buying and Selling by Quarter for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.